Posts by: Forest Ray

Forest Ray

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

October 23, 2020October 23, 2020

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS

News

Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS). With ... Read more

October 13, 2020October 13, 2020

Phase 2 Study of Pegcetacoplan in Recently Diagnosed Patients Opens

News

A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is now enrolling patients, Apellis Pharmaceuticals, the therapy’s developer, announced in a ... Read more

September 23, 2020September 23, 2020

FightMND Grant Awards Further Work Into ALS, Other Motor Neuron Diseases

News

Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people with amyotrophic lateral sclerosis (ALS), and other motor neuron diseases. ... Read more

September 21, 2020September 22, 2020

Novus Acquires Anelixis, Plans to Move AT-1501 Into Phase 2 Trial for ALS

News

Novus Therapeutics has acquired Anelixis Therapeutics and its portfolio, including the antibody AT-1501, a potential treatment for amyotrophic lateral sclerosis (ALS) that the company is planning to move into a Phase 2 ... Read more

September 17, 2020September 21, 2020

Investigational Treatment IPL344 Safely Slows ALS Progression in Small Phase 1/2a Trial

News

IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a ... Read more

September 15, 2020September 15, 2020

Helixmith Planning Phase 2 Trial of Engensis, Potential Gene Therapy for ALS

News

Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press ... Read more

September 10, 2020September 10, 2020

RESCUE-ALS Phase 2 Trial Completes Enrollment Ahead of Schedule

News

Patient enrollment is now complete for the Phase 2 clinical trial of Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for amyotrophic lateral sclerosis (ALS). The trial, named RESCUE-ALS (NCT04098406) will ... Read more

September 8, 2020September 8, 2020

Cause of WWII-era ALS Cluster on Guam May Be Younger Cycad Seeds

News

Younger cycad seeds can contain more toxins than older seeds, and their widespread consumption by people on occupied Guam during World War II could be the environmental origin of ... Read more

September 4, 2020September 4, 2020

First Patient Enrolled in Phase 1 Gene Therapy Study in Ireland

News

A Phase 1 clinical trial of a gene-based therapy for amyotrophic lateral sclerosis (ALS) is now recruiting patients in one of its European centers. The Clinical Research Facility at St ... Read more

September 1, 2020September 1, 2020

Same But Different Photo Contest Celebrates People With Rare Diseases

News, syndicated

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme ... Read more

Pin It on Pinterest